Göm menyn

Publications for Agneta Jansson

Co-author map based on Web of Sciences articles 2007-

Publications mentioned in social media 14 times*

Journal Articles

Erik Hilborn, Olle Stål and Agneta Jansson
  Estrogen and androgen-converting enzymes 17 beta-hydroxysteroid dehydrogenase and their involvement in cancer: with a special focus on 17 beta-hydroxysteroid dehydrogenase type 1, 2, and breast cancer
  OncoTarget, 2017, 8(18), 30552-30562.
   Fulltext  PDF  
 Web of Science® Times Cited: 3

Erik Hilborn, Olle Stål, Andrey Alexeyenko and Agneta Jansson
  The regulation of hydroxysteroid 17 beta-dehydrogenase type 1 and 2 gene expression in breast cancer cell lines by estradiol, dihydrotestosterone, microRNAs, and genes related to breast cancer
  OncoTarget, 2017, 8(37), 62183-62194.
   Fulltext  PDF  
 Web of Science® Times Cited: 1

Erik Hilborn, Jelena Gacic, Tommy Fornander, Bo Nordenskjöld, Olle Stål and Agneta Jansson
  Androgen receptor expression predicts beneficial tamoxifen response in oestrogen receptor-alpha-negative breast cancer
  British Journal of Cancer, 2016, 114(3), 248-255.
   Fulltext  PDF  
 Web of Science® Times Cited: 14

Erik Hilborn, Tove Sivik, Tommy Fornander, Olle Stål, Bo Nordenskjöld and Agneta Jansson
  C-X-C ligand 10 and C-X-C receptor 3 status can predict tamoxifen treatment response in breast cancer patients
  Breast Cancer Research and Treatment, 2014, 145(1), 73-82.
   Fulltext  PDF  
 Web of Science® Times Cited: 6

Fredrik Jerhammar, Ann-Charlotte Johansson, Rebecca Ceder, Jenny Welander, Agneta Jansson, Roland C. Grafstrom, Peter Söderkvist and Karin Roberg
  YAP1 is a potential biomarker for cetuximab resistance in head and neck cancer
  Oral Oncology, 2014, 50(9), 832-839.
 Web of Science® Times Cited: 18

Hans Olsson, Agneta Jansson, Birgitta Holmlund and Cecilia Gunnarsson
  Methods for evaluating HER2 status in breast cancer: comparison of IHC, FISH, and real-time PCR analysis of formalin-fixed paraffin-embedded tissue
  Pathology and Laboratory Medicine International, 2013, 5, 31-37.
   Fulltext  PDF  

Tove Sivik, Cecilia Gunnarsson, Tommy Fornander, Bo Nordenskjöld, Lambert Skoog, Olle Stål and Agneta Jansson
  17β-hydroxysteroid dehydrogenase type 14 is a predictive marker for tamoxifen response in oestrogen receptor positive breast cancer
  PLoS ONE, 2012, 7(7), e40568.
   Fulltext  PDF  
 Web of Science® Times Cited: 6

Tove Sivik, Svante Vikingsson, Henrik Gréen and Agneta Jansson
  Expression Patterns of 17β-Hydroxysteroid Dehydrogenase 14 in Human Tissues
  Hormone and Metabolic Research, 2012, 44(13), 949-956.
   Fulltext  PDF  
 Web of Science® Times Cited: 9

Tove Sivik and Agneta Jansson
  Progesterone and levonorgestrel regulate expression of 17 beta HSD-enzymes in progesterone receptor positive breast cancer cell line T47D
  Biochemical and Biophysical Research Communications - BBRC, 2012, 422(1), 109-113.
   Fulltext  PDF  
 Web of Science® Times Cited: 2

Tove Sivik, Svante Vikingsson, Henrik Greén and Agneta Jansson
  A validated and rapid high-performance liquidchromatography method for the quantification ofconversion of radio-labelled sex steroids
  Hormone Molecular Biology and Clinical Investigation, 2010, 3(1), 375-381.

Piiha-Lotta Jerevall, Agneta Jansson, Tommy Fornander, Lambert Skoog, Bo Nordenskjöld and Olle Stål
  Predictive relevance of HOXB13 protein expression for tamoxifen benefit in breast cancer
  Breast Cancer Research, 2010, 12(4), .
   Fulltext  PDF  
 Web of Science® Times Cited: 13

Agneta Jansson
  17Beta-hydroxysteroid dehydrogenase enzymes and breast cancer
 Web of Science® Times Cited: 28

Agneta Jansson, Lovisa Delander, Cecilia Gunnarsson, Tommy Fornander, Lambert Skoog, Bo Nordenskjöld and Olle Stål
  Ratio of 17HSD1 to 17HSD2 protein expression predicts the outcome of tamoxifen treatment in postmenopausal breast cancer patients.
  Clinical Cancer Research, 2009, 15(10), 3610-3616.
 Web of Science® Times Cited: 20

Cecilia Gunnarsson, Piiha-Lotta Jerevall, Karl Hammar, Birgit Olsson, Bo Nordenskjöld, Agneta Jansson and Olle Stål
  Amplification of HSD17B1 has prognostic significance in postmenopausal breast cancer
  Breast Cancer Research and Treatment, 2008, 108(1), 35-41.
 Web of Science® Times Cited: 25

Agneta Jansson, Jonas Carlsson, Anette Olsson, Petter Storm, Sara Margolin, Cecilia Gunnarsson, Marie Stenmark Askmalm, Annika Lindblom, Bengt Persson and Olle Stål
  A new polymorphism in the coding region of exon four in HSD17B2 in relation to risk of sporadic and hereditary breast cancer
  Breast Cancer Research and Treatment, 2007, 106(1), 57-64.
 Web of Science® Times Cited: 7

Agneta Jansson, Cecilia Gunnarsson, Maja Cohen, Tove Sivik and Olle Stål
  17β-hydroxysteroid dehydrogenase 14 affects estradiol levels in breast cancer cells and is a prognostic marker in estrogen receptor-positive breast cancer
  Cancer Research, 2006, 66(23), 11471-11477.
 Web of Science® Times Cited: 49

Cecilia Gunnarsson, Agneta Jansson, Birgitta Holmlund, Lilianne Ferraud, Bo Nordenskjöld, Lars Erik Rutqvist, Lambert Skoog and Olle Stål
  Expression of COX-2 and steroid converting enzymes in breast cancer
  Oncology Reports, 2006, 16(2), 219-224.
 Web of Science® Times Cited: 11

B Iacopetta, A Russo, V Bazan, G Dardanoni, N Gebbia, T Soussi, D Kerr, H Elsaleh, R Soong, D Kandioler, E Janschek, S Kappel, M Lung, C-S S Leung, J M Ko, Xiao-Feng Sun, Agneta Jansson, AJ Shorthouse, ML Silverman, S Kato and C Ishioka
  Functional categories of TP53 mutation in colorectal cancer: results of an International Collaborative Study
  Annals of Oncology, 2006, 17, 842-847.
 Web of Science® Times Cited: 59

Agneta Jansson, Cecilia Gunnarsson and Olle Stål
  Proliferative responses to altered 17β-hydroxysteroid dehydrogenase (17HSD) type 2 expression in human breast cancer cells are dependent on endogenous expression of 17HSD type 1 and the oestradiol receptors
  Endocrine-Related Cancer, 2006, 13(3), 875-884.
 Web of Science® Times Cited: 14

Agneta Jansson, Gunnar Arbman and Xiao-Feng Sun
  mRNA and protein expression of PUMA in sporadic colorectal cancer.
  Oncology Reports, 2004, 12(6), 1245-1249.
 Web of Science® Times Cited: 10

Agneta Jansson, Gunnar Arbman, Hong Zhang and Xiao-Feng Sun
  Combined deficiency of hMLH1, hMSH2, hMSH3 and hMSH6 is an independent prognostic factor in colorectal cancer
  International Journal of Oncology, 2003, 22(1), 41-49.
 Web of Science® Times Cited: 15

Agneta Jansson, Anna Emterling, Gunnar Arbman and Xiao-Feng Sun
  Noxa in colorectal cancer: A study on DNA, mRNA and protein expression
  Oncogene, 2003, 22(30), 4675-4678.
 Web of Science® Times Cited: 17

Agneta Jansson and Xiao-Feng Sun
  Bax expression decreases significantly from primary tumor to metastasis in colorectal cancer
  Journal of Clinical Oncology, 2002, 20(3), 811-816.
 Web of Science® Times Cited: 41

Gunnar Adell, Hong Zhang, Agneta Jansson, Xiao-Feng Sun, Olle Stål and Bo Nordenskjöld
  Decreased tumor cell proliferation as an indicator of the effect of preoperative radiotherapy of rectal cancer
  International Journal of Radiation Oncology, Biology, Physics, 2001, 50(3), 659-663.
 Web of Science® Times Cited: 34

Agneta Jansson, Massamiliano Gentile and Xiao-Feng Sun
  p53 mutations are present in colorectal cancer with cytoplasmic p53 accumulation
  International Journal of Cancer, 2001, 92(3), 338-341.
 Web of Science® Times Cited: 25

Sofia Evertsson, Zsuzsa Bartik, Hong Zhang, Agneta Jansson and Xiao-Feng Sun
  Apoptosis in relation to proliferating cell nuclear antigen and Dukes' stage in colorectal adenocarcinoma
  International Journal of Oncology, 1999, 15(1), 53-58.
 Web of Science® Times Cited: 36

Xiao-Feng Sun, Hong Zhang, John Carstensen, Agneta Jansson and Bo Nordenskjöld
  Heat shock protein 72/73 in relation to cytoplasmic p53 expression and prognosis in colorectal adenocarcinomas
  International Journal of Cancer, 1997, 74(6), 600-604.
 Web of Science® Times Cited: 31

Agneta Jansson and Xiao-Feng Sun
  Ki-67 expression in relation to clinicopathological variables and prognosis in colorectal adenocarcinomas
  Acta Pathologica, Microbiologica et Immunologica Scandinavica (APMIS), 1997, 105(9), 730-734.
 Web of Science® Times Cited: 49

Conference Articles

Tove Sivik, Olle Stål, T Fornander, L Skoog, Bo Nordenskjöld and Agneta Jansson
  Significance of 17bHSD Type 14 as a Predictive Factor for Adjuvant Tamoxifen Treatment Response in Breast Cancer in CANCER RESEARCH, vol 69, issue 24, pp 596S-597S

Ph.D. Theses

Erik Hilborn
  The role of the androgen receptor and hydroxysteroid 17β dehydrogenase in breast cancer: Impact on tamoxifen treatment

  Fulltext PDF

Tove Sivik
  Elucidating the role of 17β hydroxysteroid dehydrogenase type 14 in normal physiology and in breast cancer

  Fulltext PDF

Fredrik Jerhammar
  Predictive Markers of Treatment Resistance in Head and Neck Squamous Cell Carcinoma

  Fulltext PDF

Piiha-Lotta Jerevall
  Homeobox B13 in breast cancer: Prediction of tamoxifen benefit

  Fulltext PDF

Agneta Jansson
  Molecular alterations in colorectal cancer

* Social media data based on publications from 2011 to present and with a DOI; data delivered by Altmetric.com.


Responsible for this page: Peter Berkesand
Last updated: 2017-02-21